Industry perspective
Peptides at a policy crossroads.
A new draft enforcement-discretion policy notice adds context to the peptide conversation.

The Federal Register published notice of the availability of a draft HHS enforcement-discretion policy concerning 503A compounding using certain peptide bulk substances. A draft policy notice does not establish that CHP has launched a program, received authorization, or demonstrated a clinical benefit.
A question to take with you.
What does the exact policy say about the substance, setting and conditions involved? Read the primary document before drawing a conclusion.
An editorial summary, not independent medical or investment advice. External source content is not a statement of CHP’s operational status.
Back to news & perspectives↗
HEAL WELL. AGE WELL. LIVE LONGER.